Literature DB >> 15006493

Membrane phospholipids and cytokine interaction in schizophrenia.

Jeffrey K Yao1, Daniel P van Kammen.   

Abstract

Although the potential key role that lipids may have in schizophrenia is not fully understood, multiple lines of evidence to date implicate the lipid environment in the behavior of neurotransmitter systems. Decreased phospholipid polyunsaturated fatty acids (PUFAs) have been demonstrated in both brain and peripheral membranes in schizophrenia, which is consistent with the hypothesis of myelin-related dysfunction in schizophrenia. Membrane defects, such as those induced by decreased PUFAs in phospholipids, can significantly alter a broad range of membrane functions and ipso facto behavior through multiple "downstream" effects. A number of putative mechanisms have been identified to explain the decreased PUFAs in schizophrenia, notably the increased turnover of phospholipids and decreased incorporation of arachidonic acid (AA) in membranes. In addition to increased oxidative stress, altered immune function may also be responsible for increased phospholipase activities. This association is particularly relevant in relation to phospholipids/PUFA, as AA can be converted to a variety of biologically active compounds, such as eicosanoids, which serve as potent messengers in regulating the inflammatory response, as well as endocannabinoids, which may affect schizophrenic psychopathology. Direct evidence of immune changes in some patients with schizophrenia have come to light, particularly in the activities of several cytokines known to be altered in autoimmune dysfunction. Given the diverse physiological function of AA, the specific behavioral symptomatology of schizophrenia is related mostly to the effect of AA changes that regulates neurodevelopment, neurotransmitter homeostasis, phosphatidylinositol signaling, and neuromodulatory actions of endocannabinoids in schizophrenia. Hence, in the current conceptualization, AA may be at a nexus point in the cascade leading to the syndrome of schizophrenia and represents a common biochemical pathway leading to the varied symptomatology of this disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006493     DOI: 10.1016/S0074-7742(04)59012-8

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  18 in total

1.  Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study.

Authors:  Paulo L Lizano; Matcheri S Keshavan; Neeraj Tandon; Ian T Mathew; Suraj Sarvode Mothi; Debra M Montrose; Jeffrey K Yao
Journal:  Schizophr Res       Date:  2015-12-11       Impact factor: 4.939

Review 2.  The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.

Authors:  Gerwyn Morris; Ken Walder; Basant K Puri; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 3.  Inflammation and schizophrenia.

Authors:  Brian Kirkpatrick; Brian J Miller
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

5.  Diffusion Imaging of White Matter In Schizophrenia: Progress and Future Directions.

Authors:  Katherine H Karlsgodt
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-05

6.  Semantic memory in schizophrenia: association with cell membrane essential fatty acids.

Authors:  Ruth Condray; Jeffrey K Yao; Stuart R Steinhauer; Daniel P van Kammen; Ravinder D Reddy; Lisa A Morrow
Journal:  Schizophr Res       Date:  2008-10-16       Impact factor: 4.939

7.  Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

Authors:  S Smesny; B Milleit; U-C Hipler; C Milleit; M R Schäfer; C M Klier; M Holub; I Holzer; G E Berger; M Otto; I Nenadic; M Berk; P D McGorry; H Sauer; G P Amminger
Journal:  Mol Psychiatry       Date:  2013-03-12       Impact factor: 15.992

8.  Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  J K Yao; G G Dougherty; R D Reddy; M S Keshavan; D M Montrose; W R Matson; S Rozen; R R Krishnan; J McEvoy; R Kaddurah-Daouk
Journal:  Mol Psychiatry       Date:  2009-04-28       Impact factor: 15.992

9.  Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis.

Authors:  Bart D Peters; Marise W J Machielsen; Wendela P Hoen; Matthan W A Caan; Anil K Malhotra; Philip R Szeszko; Marinus Duran; Silvia D Olabarriaga; Lieuwe de Haan
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

10.  Expression of cellular prion protein (PrP(c)) in schizophrenia, bipolar disorder, and depression.

Authors:  Serge Weis; Johannes Haybaeck; Jeannette R Dulay; Ida C Llenos
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.